Companies Generation Bio Co.
Generation Bio (GBIO): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Email me Generation Bio Co.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $3,966,762FY2022
- $2,315,263FY2023
- $1,808,274FY2024
CEO total pay was $1,808,274 in fiscal 2024, down from $2,315,263 in fiscal 2023.
FY2024: salary $655,301 · bonus $0 · stock awards $0 · option awards $790,358
Order GBIO
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Geoff McDonough | $655,301 | $0 | $0 | $790,358 | $360,416 | $0 | $2,199 | $1,808,274 |
| President and Chief Executive Officer | ||||||||
| Matthew Stanton | 519,167 | 0 | 0 | 250,807 | 207,667 | 0 | 15,397 | 993,038 |
| Chief Scientific Officer | ||||||||
| Antionette Paone | 475,141 | 0 | 0 | 250,807 | 190,056 | 0 | 15,958 | 931,962 |
| Chief Operating Officer | ||||||||
| Phillip Samayoa | 475,000 | 0 | 0 | 250,807 | 190,000 | 0 | 15,956 | 931,763 |
| Chief Strategy Officer | ||||||||
| Matthew Norkunas | 472,442 | 0 | 0 | 250,807 | 188,977 | 0 | 2,020 | 914,246 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Geoff McDonough | $1,808,274 | $2,315,263 | $3,966,762 | ↓ −506,989 |
| Matthew Stanton | 993,038 | 1,151,338 | 1,615,614 | ↓ −158,300 |
| Antionette Paone | 931,962 | 1,070,098 | 1,582,356 | ↓ −138,136 |
| Phillip Samayoa | 931,763 | 914,874 | 1,482,616 | ↑ +16,889 |
| Matthew Norkunas | 914,246 | 1,144,331 | 1,571,892 | ↓ −230,085 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The goals of our compensation programs are to pay for performance and ensure that the interests of our employees, including our NEOs, are aligned with the interests of our stockholders and our business goals, and that the total compensation paid to each of our NEOs is fair, reasonable, and competitive. We aim to target the 50th percentile of our peer group for each compensation element for our NEOs.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Matthew Norkunas | Option | 381 | 30.73 | — |
| Phillip Samayoa | Option | 1,375 | 30.25 | — |
| Matthew Stanton | Option | 1,875 | 30.73 | — |
| Antionette Paone | Option | 1,968 | 30.25 | — |
| Matthew Norkunas | Option | 2,051 | 30.25 | — |
| Phillip Samayoa | Option | 3,750 | 35.66 | — |
| Matthew Stanton | Option | 4,593 | 30.25 | — |
| Phillip Samayoa | RSU | 10,317 | — | 10,936 |
| Antionette Paone | RSU | 14,324 | — | 15,183 |
| Matthew Stanton | RSU | 15,059 | — | 15,963 |
| Geoff McDonough | Option | 15,687 | 30.25 | — |
| Matthew Norkunas | RSU | 16,732 | — | 17,736 |
| Phillip Samayoa | Option | 18,345 | 6.49 | — |
| Antionette Paone | Option | 20,625 | 6.49 | — |
| Phillip Samayoa | Option | 20,637 | 4.71 | — |
| Antionette Paone | Option | 28,649 | 4.71 | — |
| Matthew Norkunas | Option | 30,121 | 4.71 | — |
| Matthew Stanton | Option | 30,121 | 4.71 | — |
| Antionette Paone | Option | 34,375 | 5.23 | — |
| Matthew Norkunas | Option | 37,185 | 6.49 | — |
| Matthew Stanton | Option | 37,185 | 6.49 | — |
| Matthew Norkunas | Option | 38,154 | 1.39 | — |
| Antionette Paone | Option | 38,154 | 1.39 | — |
| Phillip Samayoa | Option | 38,154 | 1.39 | — |
| Matthew Stanton | Option | 38,154 | 1.39 | — |
| Geoff McDonough | RSU | 47,459 | — | 50,307 |
| Phillip Samayoa | Option | 48,125 | 5.53 | — |
| Geoff McDonough | Option | 94,921 | 4.71 | — |
| Geoff McDonough | Option | 117,185 | 6.49 | — |
| Geoff McDonough | Option | 120,234 | 1.39 | — |
| Matthew Norkunas | Option | 160,650 | 1.86 | — |
| Antionette Paone | Option | 160,650 | 1.86 | — |
| Phillip Samayoa | Option | 160,650 | 1.86 | — |
| Matthew Stanton | Option | 160,650 | 1.86 | — |
| Geoff McDonough | Option | 506,250 | 1.86 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jason RhodesIndependent · Board Chair · Talent Committee (Chair) | $85,000 | $0 | $166,476 | — | — | $251,476 |
| Charles RowlandIndependent · Audit Committee (Chair) | 55,000 | 0 | 166,476 | — | — | 221,476 |
| Ron CooperIndependent · Nominating and Corporate Governance Committee (Chair) | 48,000 | 0 | 166,476 | — | — | 214,476 |
| Anthony Quinn, M.B. Ch.B., Ph.DIndependent · Audit Committee | 47,500 | 0 | 166,476 | — | — | 213,976 |
| Gustav ChristensenIndependent · Audit Committee | 47,500 | 0 | 166,476 | — | — | 213,976 |
| Donald Nicholson, Ph.DIndependent · Talent Committee | 47,500 | 0 | 166,476 | — | — | 213,976 |
| Catherine Stehman-Breen, M.DIndependent · Talent Committee | 47,500 | 0 | 166,476 | — | — | 213,976 |
| Jeffrey Jonas, M.DIndependent · Nominating and Corporate Governance Committee | 44,000 | 0 | 166,476 | — | — | 210,476 |
| Dannielle AppelhansIndependent · Nominating and Corporate Governance Committee | 44,000 | 0 | 166,476 | — | — | 210,476 |
| Geoff McDonough, M.DEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 7,500 / 4,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $466,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $466,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Generation Bio as a peer
Companies that benchmark against GBIO
1 company names GBIO as a compensation peer
- Adverum Biotechnologies, Inc.ADVMFY2024
Each company listed discloses GBIO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GBIO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Peer reciprocity
Of the companies Generation Bio Co. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer’s own current proxy has been read — each mark is cited in the register to that peer’s filing. A dash means the peer’s current proxy was read and names no reciprocal group including Generation Bio Co..
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Verve Therapeutics, Inc. | 2024 | Sekar Kathiresan | $639,231 | $1,683,000 | $4,727,372 | $378,972 | $7,442,663 |
| 2 | Entrada Therapeutics, Inc. | 2025 | Dipal Doshi | 635,000 | 1,387,428 | 1,452,059 | 349,250 | 3,837,737 |
| 3 | Poseida Therapeutics, Inc. | 2023 | Mark Gergen | 611,667 | 1,442,285 | 1,413,936 | 336,420 | 3,818,018 |
| 4 | Voyager Therapeutics, Inc. | 2025 | Alfred Sandrock | 674,903 | 611,900 | 843,900 | 361,917 | 2,508,370 |
| 5 | Cabaletta Bio, Inc. | 2025 | Steven Nichtberger | 659,550 | 0 | 1,266,978 | 446,982 | 2,401,555 |
| 6 | Editas Medicine, Inc. | 2025 | Gilmore O'Neill | 686,574 | 0 | 1,282,937 | 375,164 | 2,353,655 |
| 7 | Precision BioSciences, Inc. | 2025 | Michael Amoroso | 650,875 | 1,025,086 | 0 | 0 | 2,189,467 |
| 8 | Tenaya Therapeutics, Inc. | 2025 | Faraz Ali | 664,173 | 141,924 | 755,507 | 319,275 | 1,881,396 |
| 9 | Caribou Biosciences, Inc. | 2025 | Rachel Haurwitz | 667,534 | 192,818 | 654,541 | 0 | 1,840,965 |
| 10 | Generation Bio Co. | 2024 | Geoff McDonough | 655,301 | 0 | 790,358 | 360,416 | 1,808,274 |
| 11 | Adicet Bio, Inc. | 2025 | Chen Schor | 646,294 | 0 | 512,079 | 284,592 | 1,465,747 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Generation Bio Co. | not disclosed | not disclosed | not disclosed | Compensia |
| Adicet Bio, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Cabaletta Bio, Inc. | 114.49% | Option 100 | not disclosed | Aon |
| Caribou Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Editas Medicine, Inc. | 91% | Options 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Entrada Therapeutics, Inc. | not disclosed | not disclosed | No | Pay Governance |
| Poseida Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Precision BioSciences, Inc. | 115% | RSU 100 | not disclosed | Aon |
| Tenaya Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Verve Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford Data & Analytics from Aon plc |
| Voyager Therapeutics, Inc. | 97.5% | not disclosed | No | Alpine Rewards, LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-04 | 38,082,392 | 359,912 | 22,112 | 99.06% | Passed |
| 2024 | 2024-06-06 | 47,772,176 | 373,246 | 15,125 | 99.22% | Passed |
| 2023 | 2023-06-08 | 57,779,162 | 94,302 | 15,033 | 99.84% | Passed |
| 2021 | 2021-06-09 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-06-04 | 99.06%a |
| 2024 | 2024-06-06 | 99.22%b |
| 2023 | 2023-06-08 | 99.84%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 8 : 1 |
|---|---|
| CEO total compensation | — |
| Median employee compensation | $218,104 |
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (34 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Geoff McDonough. DEF 14A, filed 2025-04-23. Section “Summary Compensation Table” · page 43. As printed: 1,808,274. View filing ↗
- Section 01, Matthew Stanton. DEF 14A, filed 2025-04-23. Section “Summary Compensation Table” · page 43. As printed: 993,038. View filing ↗
- Section 01, Antionette Paone. DEF 14A, filed 2025-04-23. Section “Summary Compensation Table” · page 43. As printed: 931,962. View filing ↗
- Section 01, Phillip Samayoa. DEF 14A, filed 2025-04-23. Section “Summary Compensation Table” · page 43. As printed: 931,763. View filing ↗
- Section 01, Matthew Norkunas. DEF 14A, filed 2025-04-23. Section “Summary Compensation Table” · page 43. As printed: 914,246. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2025-04-23. Section “CEO Pay Ratio”. As printed: 8 : 1. View filing ↗
- Section 08, Jason Rhodes. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 251,476. View filing ↗
- Section 08, Charles Rowland. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 221,476. View filing ↗
- Section 08, Ron Cooper. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 214,476. View filing ↗
- Section 08, Anthony Quinn, M.B. Ch.B., Ph.D. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 213,976. View filing ↗
- Section 08, Gustav Christensen. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 213,976. View filing ↗
- Section 08, Donald Nicholson, Ph.D. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 213,976. View filing ↗
- Section 08, Catherine Stehman-Breen, M.D. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 213,976. View filing ↗
- Section 08, Jeffrey Jonas, M.D. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 210,476. View filing ↗
- Section 08, Dannielle Appelhans. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 210,476. View filing ↗
- Section 08, Geoff McDonough, M.D. DEF 14A, filed 2025-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-05. Item 5.07 · say-on-pay result. As reported: 99.06% (votes for as printed: 38,082,392). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-07. Item 5.07 · say-on-pay result. As reported: 99.22% (votes for as printed: 47,772,176). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-09. Item 5.07 · say-on-pay result. As reported: 99.84% (votes for as printed: 57,779,162). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 466,000 + equity 0 + all other 0 = 466,000, summed across the director compensation table rows.
- Verve Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-25. CEO total compensation as printed in Verve Therapeutics, Inc.'s own proxy. As printed: 7,442,663. View filing ↗
- Entrada Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Entrada Therapeutics, Inc.'s own proxy. As printed: 3,837,737. View filing ↗
- Poseida Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Poseida Therapeutics, Inc.'s own proxy. As printed: 3,818,018. View filing ↗
- Voyager Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Voyager Therapeutics, Inc.'s own proxy. As printed: 2,508,370. View filing ↗
- Cabaletta Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cabaletta Bio, Inc.'s own proxy. As printed: 2,401,555. View filing ↗
- Editas Medicine, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Editas Medicine, Inc.'s own proxy. As printed: 2,353,655. View filing ↗
- Precision BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Precision BioSciences, Inc.'s own proxy. As printed: 2,189,467. View filing ↗
- Tenaya Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Tenaya Therapeutics, Inc.'s own proxy. As printed: 1,881,396. View filing ↗
- Caribou Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-05-01. CEO total compensation as printed in Caribou Biosciences, Inc.'s own proxy. As printed: 1,840,965. View filing ↗
- Generation Bio Co. (subject), Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Generation Bio Co.'s own proxy. As printed: 1,808,274. View filing ↗
- Adicet Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Adicet Bio, Inc.'s own proxy. As printed: 1,465,747. View filing ↗
- Section 10a, Editas Medicine, Inc. reciprocity. DEF 14A. Editas Medicine, Inc.'s most recent proxy was read; its disclosed peer group does not include Generation Bio Co.. View filing ↗
- Section 10a, Voyager Therapeutics, Inc. reciprocity. DEF 14A. Voyager Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Generation Bio Co.. View filing ↗